It is a prime concern of Evotec that all relevant target groups receive the same information at the same time. This implies communicating in both English and German.

Please find below the most recent corporate news, ad hoc releases and other announcements of our Company.

 

2019

Evotec and Galapagos enter into collaboration in the field of Fibrosis
Nerina Coppini, 7 February 2019

Collaboration comprises licence agreement for a programme developed by Evotec as well as its drug discovery capabilities Evotec receives undisclosed upfront payment, adn is eligible for potential milestones as well as royalty payments

Evotec receives milestone payment for start of Phase II clinical trial
Nerina Coppini, 24 January 2019

Evotec's partner, Second Genome, begins a Phase II Clinical trial for NASH with licensed molecule,

 

Other announcements

Merger

The following annoucement has been published in the German Federal Gazette in accordance with the German Conversion Act (Umwandlungsgesetz) in 2013. Pursuant to the German Conversion Act, certain transaction intended by Evotec AG, e.g. up-stream mergers, have to be announced in the Federal Gazette (Bundesanzeiger).

Contact us

Gabriele Hansen

VP, Corporate Communications & Investor Relations

T +49 40 560 81 255 F +49 40 560 81 333 vCard

Katja Werner

Investor Relations Associate

T +49 40 560 81 210 F +49 40 560 81 333 vCard